摘要
目的：通过检测非小细胞肺癌（non—small cell lung cancer，NSCLC）组织中以及癌旁肺组织中Smad4mRNA的表达，分析其与不同临床病理特征之间的关系，探讨Smad 4 mRNA在非小细胞肺癌发生、发展及转移中的作用。方法：本实验共收集40例标本作为实验组，其中男性22例，女性18例；年龄为41～68岁，平均（55．3±7．1）岁。选取18例距肿瘤边缘2cm以上的癌旁肺组织作为对照组，采用实时定量PCR（Real—time PCR）技术检测Smad4 mRNA的表达。结果：Smad4 mRNA在实验组中非小细胞肺癌的表达量（2．2425±0．6057）低于癌旁肺组织（对照组）的表达量（4．4850±1．0648，P〈0．001）。Smad4mRNA在不同年龄、性别、不同病理类型NSCLC的中，差异无统计学意义。Smad4mRNA在低分化非小细胞肺癌中的表达量为1．9648±0．5170，在高、中分化的非小细胞肺癌中的表达量为2．5495±0．5545，二组比较（P=0．0014）。Smad4mRNA在无淋巴结转移的非小细胞肺癌表达量为2．4938±0．5502，在有淋巴结转移的非小细胞肺癌中的表达量为1．8656±0．4859，二组比较（P=0．0007）。Smad4mRNA在有胸膜侵犯的非小细胞肺癌中的表达量为1．9683-＋0．5483，在无胸膜侵犯的非小细胞肺癌中的表达量为2．4668±0．5657，二组比较（P=0．0078），Smad4 mRNA在Ⅲ期和Ⅳ期非小细胞肺癌中的表达量为1．9268±0．6058，在Ⅰ期和Ⅱ期非小细胞肺癌中表达量为2．5281±0．4516，二组比较（P=0．0010），本组患者随访时间为10～76个月，40例非小细胞肺癌患者术后生存3年以上者25例，占62．50％、提示非小细胞肺癌中Smad4 mRNA表达与患者预后相关（x^2=16．9620，P〈0．0001）。结论：Smad4 mRNA在非小细胞肺癌组织中低表达，Smad4 mRNA在非小细胞肺癌的发生发展中可能具有重要作用，检测Smad4 mRNA可能对判断非小细胞肺癌的预后有一定的价值．
Objective： To detect the expression of Smad4 mRNA in non-small cell lung cancer （NSCLC）, to analyze the expression and the relationship between Smad4 mRNA and different clinicopathologic characteristics, and to investigate the development and metastasis of Smad4 mRNA in non-small cell lung cancer. Methods： The study included 40 cases of NSCLC as the experimental group and 18 cases of normal lung tissues as the control, which used real-time quantitative polymerase chain reaction （ PCR ） to detect the expression of Smad4 mRNA. The average age of experimental group was （ 55.3 ± 7.1 ） years （ range, 41-68 years ）. The experimental group included 22 males and 18 females, 27 cases of squamous cell carcinoma, 13 cases of adenocarcinoma, 24 cases of non-lymph node metastasis, and 16 lymph node metastasis cases. Results： The level of Smad4 mRNA expression （ 2.2425 ± 0.6057 ） in the non-small cell lung cancer was lower than that of the adjacent lung tissue （ 4.4850 ±1.0648 ） （ P〈 0.001 ） and the difference was statistically significant. The differences in Srnad4 mRNA expression in terms of differences in age, gender, and pathological type were not statistically significant. The expression in poorly differentiated carcinoma was （ 1.9648 ±0.5170 ）, the expression in the well-differentiated cells was （ 2.5495 - 0.5545 ） （ P = 0.0014 ）, and the difference was statistically significant. The expression was （ 1.8656 ± 0.4859 ） in the cases with lymph node metastasis and （ 2.4938 ± 0.5502 ） （ P = 0.0007 ） in the cases with no lymph node metastasis; the difference was statistically significant. The expression in the cases with no pleural invasion was （ 2.4668 ± 0.5657 ）, whereas it was （ 1.9683 ± 05483 ） （ P = 0.0078 ） among cases with pleural invasion. The TNM Ⅰ and Ⅱ stages were （ 2.5281 ± 0.4516 ）, whereas the TNM Ⅲ and Ⅳ stages were （ 1.9268 ± 0.6058 ） （ P= 0.0010 ）; the difference was statistically significant. The patients were followed up for 10-76 months, and 25 of the 40 patients with non-small cell lung cancer survived more than 3 years, accounting for 62.50%. Upon examination, the Smad4 mRNA expression in NSCLC was related to patient prognosis （ X^2 = 16.9620, P 〈 0.0001 ）. Conclusion： Low Smad4 mRNA expression may play an important role in the development of non-small cell lung cancer. Testing Smad4 mRNA may have a certain value in predicting the prognosis of non-small cell lung cancer.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2011年第12期700-703,共4页
Chinese Journal of Clinical Oncology
